Genomic abnormalities of TP53 define distinct risk groups of
paediatric B-cell non-Hodgkin lymphoma

J 2022

Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

NEWMAN, Alexander M; Masood ZAKA; Peixun ZHOU; Alex E BLAIN; Amy ERHORN et al.

Základní údaje

Originální název

Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

Autoři

Vydání

Leukemia, London, Nature Publishing Group, 2022, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.400

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/22:00128584

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

BURKITT-LYMPHOMACHILDRENADOLESCENTSMUTATIONSLEUKEMIAREVEALSPATHOGENESISLANDSCAPERITUXIMABDELETION

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 2. 2023 13:57, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.

Citovat

NEWMAN, Alexander M; Masood ZAKA; Peixun ZHOU; Alex E BLAIN; Amy ERHORN; Amy BARNARD; Rachel E CROSSLAND; Sarah WILKINSON; Amir ENSHAEI; De Zordi JULIAN; Fiona HARDING; Mary TAJ; Katrina M WOOD; Despina TELEVANTOU; Suzanne Dawn TURNER; G A Amos BURKE; Christine J HARRISON; Simon BOMKEN; Chris M BACON a Vikki RAND. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia. London: Nature Publishing Group, 2022, roč. 36, č. 3, s. 781-789. ISSN 0887-6924. Dostupné z: https://doi.org/10.1038/s41375-021-01444-6.

@article{2253564,
   author = {Newman, Alexander M and Zaka, Masood and Zhou, Peixun and Blain, Alex E and Erhorn, Amy and Barnard, Amy and Crossland, Rachel E and Wilkinson, Sarah and Enshaei, Amir and Julian, De Zordi and Harding, Fiona and Taj, Mary and Wood, Katrina M and Televantou, Despina and Turner, Suzanne Dawn and Burke, G A Amos and Harrison, Christine J and Bomken, Simon and Bacon, Chris M and Rand, Vikki},
   article_location = {London},
   article_number = {3},
   doi = {https://doi.org/10.1038/s41375-021-01444-6},
   keywords = {BURKITT-LYMPHOMACHILDRENADOLESCENTSMUTATIONSLEUKEMIAREVEALSPATHOGENESISLANDSCAPERITUXIMABDELETION},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma},
   url = {https://www.nature.com/articles/s41375-021-01444-6},
   volume = {36},
   year = {2022}
}

TY  - JOUR
ID  - 2253564
AU  - Newman, Alexander M - Zaka, Masood - Zhou, Peixun - Blain, Alex E - Erhorn, Amy - Barnard, Amy - Crossland, Rachel E - Wilkinson, Sarah - Enshaei, Amir - Julian, De Zordi - Harding, Fiona - Taj, Mary - Wood, Katrina M - Televantou, Despina - Turner, Suzanne Dawn - Burke, G A Amos - Harrison, Christine J - Bomken, Simon - Bacon, Chris M - Rand, Vikki
PY  - 2022
TI  - Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
JF  - Leukemia
VL  - 36
IS  - 3
SP  - 781-789
EP  - 781-789
PB  - Nature Publishing Group
SN  - 08876924
KW  - BURKITT-LYMPHOMACHILDRENADOLESCENTSMUTATIONSLEUKEMIAREVEALSPATHOGENESISLANDSCAPERITUXIMABDELETION
UR  - https://www.nature.com/articles/s41375-021-01444-6
N2  - Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.
ER  -

NEWMAN, Alexander M; Masood ZAKA; Peixun ZHOU; Alex E BLAIN; Amy ERHORN; Amy BARNARD; Rachel E CROSSLAND; Sarah WILKINSON; Amir ENSHAEI; De Zordi JULIAN; Fiona HARDING; Mary TAJ; Katrina M WOOD; Despina TELEVANTOU; Suzanne Dawn TURNER; G A Amos BURKE; Christine J HARRISON; Simon BOMKEN; Chris M BACON a Vikki RAND. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. \textit{Leukemia}. London: Nature Publishing Group, 2022, roč.~36, č.~3, s.~781-789. ISSN~0887-6924. Dostupné z: https://doi.org/10.1038/s41375-021-01444-6.

Přehled o publikaci